These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 23979133)

  • 1. Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo.
    Maussang D; Mujić-Delić A; Descamps FJ; Stortelers C; Vanlandschoot P; Stigter-van Walsum M; Vischer HF; van Roy M; Vosjan M; Gonzalez-Pajuelo M; van Dongen GA; Merchiers P; van Rompaey P; Smit MJ
    J Biol Chem; 2013 Oct; 288(41):29562-72. PubMed ID: 23979133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging ligand-dependent activation of CXCR7.
    Luker KE; Gupta M; Steele JM; Foerster BR; Luker GD
    Neoplasia; 2009 Oct; 11(10):1022-35. PubMed ID: 19794961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
    Heinrich EL; Lee W; Lu J; Lowy AM; Kim J
    J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric peptide regulators of chemokine receptors CXCR4 and CXCR7.
    Ehrlich A; Ray P; Luker KE; Lolis EJ; Luker GD
    Biochem Pharmacol; 2013 Nov; 86(9):1263-71. PubMed ID: 23973527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands.
    Luker KE; Steele JM; Mihalko LA; Ray P; Luker GD
    Oncogene; 2010 Aug; 29(32):4599-610. PubMed ID: 20531309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.
    Gravel S; Malouf C; Boulais PE; Berchiche YA; Oishi S; Fujii N; Leduc R; Sinnett D; Heveker N
    J Biol Chem; 2010 Dec; 285(49):37939-43. PubMed ID: 20956518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR7 controls competition for recruitment of β-arrestin 2 in cells expressing both CXCR4 and CXCR7.
    Coggins NL; Trakimas D; Chang SL; Ehrlich A; Ray P; Luker KE; Linderman JJ; Luker GD
    PLoS One; 2014; 9(6):e98328. PubMed ID: 24896823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The chemokine receptor CXCR7 interacts with EGFR to promote breast cancer cell proliferation.
    Salazar N; Muñoz D; Kallifatidis G; Singh RK; Jordà M; Lokeshwar BL
    Mol Cancer; 2014 Aug; 13():198. PubMed ID: 25168820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The presumed atypical chemokine receptor CXCR7 signals through G(i/o) proteins in primary rodent astrocytes and human glioma cells.
    Odemis V; Lipfert J; Kraft R; Hajek P; Abraham G; Hattermann K; Mentlein R; Engele J
    Glia; 2012 Mar; 60(3):372-81. PubMed ID: 22083878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G protein‑mediated EGFR transactivation is a common mechanism through which the CXCL12 receptors, CXCR4 and CXCR7, control human cancer cell migration.
    Zieger-Naumann K; Kuhl F; Engele J
    Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38099418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
    Khare T; Bissonnette M; Khare S
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing nanobodies targeting diverse chemokines effectively inhibit chemokine function.
    Blanchetot C; Verzijl D; Mujić-Delić A; Bosch L; Rem L; Leurs R; Verrips CT; Saunders M; de Haard H; Smit MJ
    J Biol Chem; 2013 Aug; 288(35):25173-25182. PubMed ID: 23836909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment.
    Wani N; Nasser MW; Ahirwar DK; Zhao H; Miao Z; Shilo K; Ganju RK
    Breast Cancer Res; 2014 May; 16(3):R54. PubMed ID: 24886617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells.
    Luker KE; Lewin SA; Mihalko LA; Schmidt BT; Winkler JS; Coggins NL; Thomas DG; Luker GD
    Oncogene; 2012 Nov; 31(45):4750-8. PubMed ID: 22266857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.
    Roovers RC; Laeremans T; Huang L; De Taeye S; Verkleij AJ; Revets H; de Haard HJ; van Bergen en Henegouwen PM
    Cancer Immunol Immunother; 2007 Mar; 56(3):303-317. PubMed ID: 16738850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing of CXCR7 gene represses growth and invasion and induces apoptosis in colorectal cancer through ERK and β-arrestin pathways.
    Li XX; Zheng HT; Huang LY; Shi DB; Peng JJ; Liang L; Cai SJ
    Int J Oncol; 2014 Oct; 45(4):1649-57. PubMed ID: 25051350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCR7 participates in CXCL12-induced CD34+ cell cycling through β-arrestin-dependent Akt activation.
    Torossian F; Anginot A; Chabanon A; Clay D; Guerton B; Desterke C; Boutin L; Marullo S; Scott MG; Lataillade JJ; Le Bousse-Kerdilès MC
    Blood; 2014 Jan; 123(2):191-202. PubMed ID: 24277075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells.
    Tang X; Li X; Li Z; Liu Y; Yao L; Song S; Yang H; Li C
    Tumour Biol; 2016 Oct; 37(10):13425-13433. PubMed ID: 27460092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR7 as a novel therapeutic target for advanced prostate cancer.
    Gritsina G; Yu J
    Oncogene; 2023 Mar; 42(11):785-792. PubMed ID: 36755058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CXCL12/CXCR7 signalling axis promotes proliferation and metastasis in cervical cancer.
    Xu L; Li C; Hua F; Liu X
    Med Oncol; 2021 Apr; 38(5):58. PubMed ID: 33847822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.